Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer
Affiliation
Department of Radiation Oncology, Institut d'Oncologie Thoracique, Gustave Roussy, Villejuif, FranceIssue Date
2021
Metadata
Show full item recordAbstract
NoneCitation
Levy A, Le Péchoux C, Faivre-Finn C. Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer. The Lancet Oncology . 2021 Jun;22(6):e220.Journal
Lancet OncologyDOI
10.1016/s1470-2045(21)00255-2PubMed ID
34087130Additional Links
https://dx.doi.org/10.1016/s1470-2045(21)00255-2Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/s1470-2045(21)00255-2
Scopus Count
Collections
Related articles
- Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer.
- Authors: Xie L, Fan X, Qian B
- Issue date: 2021 Jun
- Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer - Authors' reply.
- Authors: Grønberg BH, Langer SW, Nyman J, Halvorsen TO
- Issue date: 2021 Jun
- [A Phase I/II Study of Chemotherapy Concurrent with Twice-daily Radiotherapy Schedules by Intensity Modulated Radiation Therapy Using Simultaneous Integrated Boost for Limited-stage Small Cell Lung Cancer].
- Authors: You J, Yu H, Song M, Shi C, Wang X, Zheng Y, Yu R, Shi A, Zhu G
- Issue date: 2017 Jan 20
- [Phase I Study of Etoposide and Cisplatin Chemotherapy Dose Escalation with Concurrent Twice-daily Radiotherapy for Patients with Limited-stage Small Cell Lung Cancer].
- Authors: You J, Yu H, Song M, Shi C, Wang X, Zheng Y, Yu R, Shi A, Zhu G
- Issue date: 2017 Jan 20
- Letter regarding "Once daily (OD) versus twice-daily (BID) chemoradiation for limited stage small cell lung cancer (LS-SCLC): A meta-analysis of randomized clinical trials".
- Authors: Li Z, Hu Y, Li Q
- Issue date: 2022 Dec